Skip to main content

Yaz Lawsuits Expected to Reach 25,000

By March 9, 2011July 10th, 2019Uncategorized

It is expected that more than 25,000 Yaz side effects lawsuits may be filed against Bayer before the smoke starts to clear for the drug giant.

More and more women are coming forward with lawsuits alleging that the company purposely downplayed the negative side effects of its controversial birth control pills Yaz and Yasmin — and that Bayer illegally marketed the pills to treat conditions it wasn’t approved for by the FDA. This huge number of litigants has the potential to have a devastating effect on the future of the pills’ sales in the U.S. In fact, many are expecting that the pills will be recalled as a result of the immense number of lawsuits.

However, Bayer has a contingency plan in the works that it hopes will help take the sting out of the lawsuit settlements they may be paying in the U.S. The drug company is planning on selling the controversial pills in Brazil, along with at least five other drugs that are expected to hit the market by 2015.

Unfortunately for the many women that have already suffered or lost their lives as a result of taking Yaz, the move to Brazil, as well as any potential recalls of the drugs, did not come fast enough. Women have experienced potentially life-threatening conditions such as heart attacks, strokes, deep vein thrombosis, gallbladder disease, pulmonary embolisms and blood clots after taking Yaz and Yasmin.

Bayer is stubbornly standing behind its pills, claiming that their drugs are no more dangerous than any other birth control pill on the market today. However, what may likely propel a great deal of settlements in favor of the plaintiffs is that Yaz and Yasmin boast an ingredient that does set them apart and make them different from other contraceptives. The drosperinone that was once the company’s main selling point for the pills, is what studies show is causing all of these side effects. In the end, Bayer’s blockbuster boast might be a blockbuster bust for their bottom line.